Investigational drug · Phase 2
Atibuclimab
Also called: IC14
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
5
Any phase or sponsor naming "Atibuclimab"
First trial start
2024
Mar 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Atibuclimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome
- Adult Respiratory Distress Syndrome
- Acute Lung Injury
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Acute Decompensated Heart Failure
- Arrhythmogenic Right Ventricular Dysplasia
- Arrhythmogenic Left Ventricular Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy 1
- Arrhythmogenic Cardiomyopathy
- ACM
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Atibuclimab" as an intervention, largest first.
Implicit BioscienceIndustry
NCT06513949 · 56 participants (planned) · Start Jun 17, 2026 · Primary completion Mar 1, 2029
Drug: Atibuclimab · For: Acute Respiratory Distress Syndrome; Adult Respiratory Distress Syndrome; Acute Lung Injury and 1 more
Sites: Seattle, Washington · 2 sites in all
VA Office of Research and DevelopmentFederal agency
NCT07481474 · 40 participants (planned) · Start Jan 1, 2027 · Primary completion Jun 1, 2027
Drug: Atibuclimab · For: Knee Osteoarthritis (Knee OA)
Sites: Philadelphia, Pennsylvania
Implicit BioscienceIndustry
NCT06556810 · 10 participants · Start Oct 17, 2024 · Primary completion Aug 30, 2026
Drug: Atibuclimab (IC14) · For: Acute Decompensated Heart Failure
Sites: Charlottesville, Virginia; Richmond, Virginia
Implicit BioscienceIndustry
NCT06678074 · 7 participants · Start Feb 6, 2025 · Primary completion Aug 1, 2026
Drug: Atibuclimab (IC14), 20 mg/kg intravenously, once · For: STEMI; STEMI (ST Elevation MI); STEMI - ST Elevation Myocardial Infarction (MI) and 1 more
Sites: St Louis, Missouri; Charlottesville, Virginia
Implicit BioscienceIndustry
NCT06275893 · 1 participants · Start Mar 29, 2024 · Primary completion Aug 15, 2025
Drug: IC14 · For: Arrhythmogenic Right Ventricular Dysplasia; Arrhythmogenic Left Ventricular Cardiomyopathy; Arrhythmogenic Right Ventricular Cardiomyopathy 1 and 4 more
Sites: St Louis, Missouri; Cleveland, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- CD14 in glioblastoma and temozolomide resistance: what the evidence does and does not support.
Bibi A, Lee B, Choi J, et al. · Biochem Pharmacol 2026
- Linked multimodal brain alterations in depression with suicidal risk.
Wang M, Yan Y, Tao Y, et al. · Cereb Cortex 2026
- Moving Upstream: CD14 Inhibition in Acute Decompensated Heart Failure.
Del Buono MG · JACC Basic Transl Sci 2026
- Atibuclimab (IC14) for Treatment of Acute Decompensated Heart Failure: A Phase Ib Pilot Study.
Abbate A, Golino M, Hogwood AC, et al. · JACC Basic Transl Sci 2026
- Pollutimonas rozaliensis sp. nov., a novel bacterium isolated from gold ore of the active Rozalia mine (Central Europe, Slovakia).
Nosalova L, Brestovicova S, Kiskova J, et al. · Arch Microbiol 2026
- Anaeroglomus insulsum gen. nov., sp. nov., anaerobic planctomycete, isolated from a thermal water stream.
Khomyakova MA, Merkel AY, Novikov AA, et al. · Syst Appl Microbiol 2026
Also in development for Acute Respiratory Distress Syndrome
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- rhu-pGSNrecombinant human gelsolin, Recombinant human plasma gelsolin pre-exposurePhase 22 trials
BioAegis Therapeutics Inc. · Acute Respiratory Distress Syndrome, Infections, Decompression Sickness
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- AV-001Phase 21 trial
Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.